Related references
Note: Only part of the references are listed.Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-oflife results from the phase 3 KEYNOTE-590 study
Jean-Philippe Metges et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy versus chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015
Deirdre Jill Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET ONCOLOGY (2022)
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
Y. Doki et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
Kohei Shitara et al.
NATURE (2022)
KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma
Josep Tabernero et al.
FUTURE ONCOLOGY (2021)
Immune-Checkpoint Inhibition in the Treatment of Gastro-Esophageal Cancer: A Closer Look at the Emerging Evidence
Koosha Paydary et al.
CANCERS (2021)
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Matthew J. Page et al.
INTERNATIONAL JOURNAL OF SURGERY (2021)
Sex-related differences in the efficacy of immune checkpoint inhibitors in malignancy: a systematic review and meta-analysis
Li-Ting Lai et al.
AGING-US (2021)
Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study
L. Shen et al.
ANNALS OF ONCOLOGY (2021)
Pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: Results from the DANTE trial of the German Gastric Group at the AIO and SAKK
S-E. Al-Batran et al.
ANNALS OF ONCOLOGY (2021)
JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)
R-H. Xu et al.
ANNALS OF ONCOLOGY (2021)
Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study
J. Xu et al.
ANNALS OF ONCOLOGY (2021)
Frequency of PD-L1 positivity and microsatellite instability (MSI) in the DANTE trial: Perioperative atezolizumab with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma. A randomized, open-label phase IIb trial of the German gastric group at the AIO and SAKK
C. Kopp et al.
ANNALS OF ONCOLOGY (2021)
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial
Huiyan Luo et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Efficacy and safety of camrelizumab combined with FLOT versus FLOT alone as neoadjuvant therapy in patients with resectable locally advanced gastric and gastroesophageal junction adenocarcinoma who received D2 radical gastrectomy.
Ning Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).
Rui-hua Xu et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Jong-Mu Sun et al.
LANCET (2021)
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y. Janjigian et al.
LANCET (2021)
FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients
Ye Wang et al.
FRONTIERS IN ONCOLOGY (2021)
Burden of Gastric Cancer
Aaron P. Thrift et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
A nationwide population-based study comparing survival in unresectable advanced or synchronous metastatic esophageal and gastric adenocarcinoma.
Marieke Pape et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Safety of perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: An interim safety analysis of the DANTE, a randomized, open-label phase II trial of the German Gastric Group at the AIO and the SAKK.
Salah-Eddin Al-Batran et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Interim safety analysis of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma—A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK.
Nils Homann et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Global burden of oesophageal and gastric cancer by histology and subsite in 2018
Melina Arnold et al.
GUT (2020)
Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies
Anita Mazloom et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Updated safety data of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma - A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK
S-E. Al-Batran et al.
ANNALS OF ONCOLOGY (2020)
Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study
K. Kato et al.
ANNALS OF ONCOLOGY (2020)
Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction - Safety Results from AIO-STO-0417: A randomized phase II trial of the German Gastric Group of the AIO
C. Pauligk et al.
ANNALS OF ONCOLOGY (2020)
A decade of immune-checkpoint inhibitors in cancer therapy
Caroline Robert
NATURE COMMUNICATIONS (2020)
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Takashi Kojima et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Kohei Shitara et al.
JAMA ONCOLOGY (2020)
Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for treatment of recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis
Zhe Jin et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis
Cong Chen et al.
ONCOIMMUNOLOGY (2019)
Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer
Megan Greally et al.
CLINICAL CANCER RESEARCH (2019)
Esophageal and Esophagogastric Junction Cancers, Version 2.2019
Jaffer A. Ajani et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer
So-Jin Park et al.
ORAL ONCOLOGY (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers A Systematic Review and Meta-analysis
Christopher J. D. Wallis et al.
JAMA ONCOLOGY (2019)
Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors)
Yingcheng Wu et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara et al.
LANCET (2018)
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
Fabio Conforti et al.
LANCET ONCOLOGY (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
Yelena Y. Janjigian et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis
Yixin Zhou et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Integrated genomic characterization of oesophageal carcinoma
Jihun Kim et al.
NATURE (2017)
Comparative transcriptomes of adenocarcinomas and squamous cell carcinomas reveal molecular similarities that span classical anatomic boundaries
Eric W. Lin et al.
PLOS GENETICS (2017)
Ramucirumab efficacy in first-line gastric and esophageal cancer treatment
Federico Longo et al.
TRANSLATIONAL CANCER RESEARCH (2017)
PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis
Lihu Gu et al.
PLOS ONE (2017)
Chemotherapy for advanced gastric cancer
Anna Dorothea Wagner et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2017)
Chemoimmunotherapy by combining oxaliplatin with immune checkpoint blockades reduced tumor burden in colorectal cancer animal model
Weiwei Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
E. C. Smyth et al.
ANNALS OF ONCOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives
Michael Davidson et al.
ONCOTARGETS AND THERAPY (2016)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma-025EFindividual patient data from 1775 patients in four randomised controlled trials
I. Chau et al.
ANNALS OF ONCOLOGY (2009)
Testosterone acts directly on CD4+ T lymphocytes to increase IL-10 production
SM Liva et al.
JOURNAL OF IMMUNOLOGY (2001)
Share Paper
